Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 30

1.

Recombinant GroEL enhances protective antigen-mediated protection against Bacillus anthracis spore challenge.

Sinha K, Bhatnagar R.

Med Microbiol Immunol. 2013 Apr;202(2):153-65. doi: 10.1007/s00430-012-0280-z. Epub 2012 Dec 21.

PMID:
23263010
2.

Progress and novel strategies in vaccine development and treatment of anthrax.

Chitlaru T, Altboum Z, Reuveny S, Shafferman A.

Immunol Rev. 2011 Jan;239(1):221-36. doi: 10.1111/j.1600-065X.2010.00969.x. Review.

PMID:
21198675
3.

Recent progress in the development of anthrax vaccines.

Kaur M, Bhatnagar R.

Recent Pat Biotechnol. 2011 Dec;5(3):148-59. Review.

PMID:
22360464
4.

New aspects of the infection mechanisms of Bacillus anthracis.

Zakowska D, Bartoszcze M, Niemcewicz M, Bielawska-Drózd A, Kocik J.

Ann Agric Environ Med. 2012;19(4):613-8. Review.

5.

Anthrax Toxins in Context of Bacillus anthracis Spores and Spore Germination.

Cote CK, Welkos SL.

Toxins (Basel). 2015 Aug 17;7(8):3167-78. doi: 10.3390/toxins7083167. Review.

6.

Anthrax vaccination strategies.

Cybulski RJ Jr, Sanz P, O'Brien AD.

Mol Aspects Med. 2009 Dec;30(6):490-502. doi: 10.1016/j.mam.2009.08.006. Epub 2009 Sep 1. Review.

7.

Monoclonal antibody therapies against anthrax.

Chen Z, Moayeri M, Purcell R.

Toxins (Basel). 2011 Aug;3(8):1004-19. doi: 10.3390/toxins3081004. Epub 2011 Aug 15. Review.

8.

Anti-toxin antibodies in prophylaxis and treatment of inhalation anthrax.

Schneemann A, Manchester M.

Future Microbiol. 2009 Feb;4(1):35-43. doi: 10.2217/17460913.4.1.35. Review.

9.

Glycan surface antigens from Bacillus anthracis as vaccine targets: current status and future perspectives.

Adamo R.

Expert Rev Vaccines. 2014 Jul;13(7):895-907. doi: 10.1586/14760584.2014.924404. Epub 2014 May 28. Review. Erratum in: Expert Rev Vaccines. 2015;14(8):1159.

PMID:
24867680
10.

Development of an improved vaccine for anthrax.

Leppla SH, Robbins JB, Schneerson R, Shiloach J.

J Clin Invest. 2002 Jul;110(2):141-4. Review. No abstract available.

11.

Antibodies against anthrax: mechanisms of action and clinical applications.

Froude JW 2nd, Thullier P, Pelat T.

Toxins (Basel). 2011 Nov;3(11):1433-52. doi: 10.3390/toxins3111433. Epub 2011 Nov 16. Review.

12.

Anthrax.

Mock M, Fouet A.

Annu Rev Microbiol. 2001;55:647-71. Review.

PMID:
11544370
13.

Protective immunity induced by Bacillus anthracis toxin mutant strains.

Pezard C, Sirard JC, Mock M.

Adv Exp Med Biol. 1996;397:69-72. Review. No abstract available.

PMID:
8718584
14.

Immune system paralysis by anthrax lethal toxin: the roles of innate and adaptive immunity.

Fukao T.

Lancet Infect Dis. 2004 Mar;4(3):166-70. Review.

PMID:
14998502
15.

The Bacillus anthracis Exosporium: What's the Big "Hairy" Deal?

Bozue JA, Welkos S, Cote CK.

Microbiol Spectr. 2015 Oct;3(5). doi: 10.1128/microbiolspec.TBS-0021-2015. Review.

PMID:
26542035
16.

Anthrax vaccines: past, present and future.

Turnbull PC.

Vaccine. 1991 Aug;9(8):533-9. Review.

PMID:
1771966
17.

Anthrax: the disease in relation to vaccines.

Hambleton P, Carman JA, Melling J.

Vaccine. 1984 Jun;2(2):125-32. Review.

PMID:
6442500
18.

Raxibacumab.

Mazumdar S.

MAbs. 2009 Nov-Dec;1(6):531-8. Epub 2009 Nov 29. Review.

19.

Pathophysiology of anthrax.

Frankel AE, Kuo SR, Dostal D, Watson L, Duesbery NS, Cheng CP, Cheng HJ, Leppla SH.

Front Biosci (Landmark Ed). 2009 Jan 1;14:4516-24. Review.

20.

T cell targeting by anthrax toxins: two faces of the same coin.

Paccani SR, Baldari CT.

Toxins (Basel). 2011 Jun;3(6):660-71. doi: 10.3390/toxins3060660. Epub 2011 Jun 20. Review.

Supplemental Content

Support Center